stockrowTG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- Revenue
- +70.3%
- EPS
- −73.7%
- Free cash flow
- +427.1%
- Total debt
- +204.2%
Quarter to June 2026, against a year earlier
Follow TGTX
Alert me
TG Therapeutics, Inc. (TGTX) EV/EBITDA
As of 5 November 2026, TG Therapeutics, Inc. (TGTX) trades at a EV/EBITDA of 62.0×. Over the past ten years it has ranged from 0.0× (December 2024) to 166× (March 2025); the current reading is higher than 93% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.4×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 36.4× | (68.54%) |
| FY2024 | 116× | 6.57% |
| FY2023 | 109× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Jun 2026 | 58.7× | 72.90% |
| Mar 2026 | 34.0× | (6.77%) |
| Dec 2025 | 36.4× | (32.75%) |
| Sep 2025 | 54.2× | (16.56%) |
| 42 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| TWST Twist Bioscience Corporation compare | n/m |
| SYRE Spyre Therapeutics, Inc. compare | n/m |
| CYTK Cytokinetics, Incorporated compare | n/m |
| IBRX ImmunityBio, Inc. compare | n/m |
| MDGL Madrigal Pharmaceuticals, Inc. compare | n/m |
| KRYS Krystal Biotech, Inc. compare | 34.1× |
| CAI Caris Life Sciences,�Inc. compare | 39.4× |
| TGTX TG Therapeutics, Inc. | 62.0× |
| PTGX Protagonist Therapeutics, Inc. compare | 145× |
| Biotechnology industry median | 0.7× |
| Healthcare sector median | 8.4× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)
More on TGTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement